Category: 501-36-0

Hartogh, Danja J. Den; Tsiani, Evangelia published the artcile< Health benefits of resveratrol in kidney disease: evidence from in vitro and in vivo studies>, Name: (E)-5-(4-Hydroxystyryl)benzene-1,3-diol, the main research area is resveratrol kidney disease health benefit review; fibroblasts; glomerulosclerosis; kidney disease; mesangial cells; renal cancer; renal epithelial cells; resveratrol.

A review. Different diseases and disorders that affect the kidneys include, but are not limited to, glomerulonephritis, diabetic nephropathy, polycystic kidney disease, kidney stones, renal fibrosis, sepsis, and renal cell carcinoma. Kidney disease tends to develop over many years, making it difficult to identify until much later when kidney function is severely impaired and undergoing kidney failure. Although conservative care, symptom management, medication, dialysis, transplantation, and aggressive renal cancer therapy are some of the current strategies/approaches to kidney disease treatment, new preventative targeted therapies are needed. Epidemiol. studies have suggested that a diet rich in fruits and vegetables is associated with health benefits including protection against kidney disease and renal cancer. Resveratrol, a polyphenol found in grapes and berries, has been reported to have antioxidant, anti-inflammatory, antidiabetic, hepatoprotective, neuroprotective, and anti-cancer properties. The current review summarizes the existing in vitro and in vivo animal and human studies examining the nephroprotective effects of resveratrol.

Nutrients published new progress about Kidney disease. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, Name: (E)-5-(4-Hydroxystyryl)benzene-1,3-diol.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Pastor, Raul Francisco; Restani, Patrizia; Di Lorenzo, Chiara; Orgiu, Francesca; Teissedre, Pierre-Louis; Stockley, Creina; Ruf, Jean Claude; Quini, Claudia Ines; Garcia Tejedor, Nuria; Gargantini, Raquel; Aruani, Carla; Prieto, Sebastian; Murgo, Marcelo; Videla, Rodolfo; Penissi, Alicia; Iermoli, Roberto Hector published the artcile< Resveratrol, human health and winemaking perspectives>, Computed Properties of 501-36-0, the main research area is review resveratrol wine; Resveratrol; oxidative stress; wine and health; winemaking.

A review. Resveratrol, (3, 5, 4′-trihydroxystilbene) is a non-flavonoid polyphenol stilbene synthesized by plants when damaged by infectious diseases or ionizing radiation. Although present in more than seventy plant species, grapes and wine are the major dietary contributors of resveratrol, responsible for 98% of the daily intake. In 1992, Renaud and De Lorgeril first linked wine polyphenols, including resveratrol, to the potential health benefits ascribed to regular and moderate wine consumption (the so called “”French Paradox””). Since then, resveratrol has received increasing scientific interest, leading to research on its biol. actions, and to a large number of published papers, which have been collected and discussed in this review. The relatively low amounts of resveratrol measured in wine following moderate consumption, however, may be insufficient to mitigate biol. damage, such as that due to oxidative stress. On this basis, the authors also highlight the importance of viticulture and the winemaking process to enhance resveratrol concentrations in wine in order to bolster potential health benefits.

Critical Reviews in Food Science and Nutrition published new progress about Homo sapiens. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, Computed Properties of 501-36-0.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Li, Dan; Wang, Gangcheng; Jin, Guoguo; Yao, Ke; Zhao, Zhenjiang; Bie, Liangyu; Guo, Yongjun; Li, Ning; Deng, Wenying; Chen, Xiaobin; Chen, Beibei; Liu, Yuanyuan; Luo, Suxia; Guo, Zhiping published the artcile< Resveratrol suppresses colon cancer growth by targeting the AKT/STAT3 signaling pathway>, Application In Synthesis of 501-36-0 , the main research area is resveratrol anticancer cell growth AKT STAT3 signaling colon cancer.

Colon cancer is a common type of cancer worldwide and accounts for a significant number of cancer-related deaths. Although surgical techniques and treatment strategies for colon cancer have advanced over the past two decades, the prognosis has not improved considerably. Resveratrol, a natural stilbene compound, possesses antioxidant, cardioprotective and anticancer properties. However, the role of resveratrol in colon cancer has not been fully elucidated. The present study demonstrated that resveratrol inhibited cell proliferation and colony growth in DLD1 and HCT15 colon cancer cells, but did not affect normal colon epithelial cells. The resveratrol-mediated inhibition of cell proliferation correlated with an induction of apoptosis and with G1 phase cell cycle arrest in colon cancer cells. Addnl., resveratrol treatment decreased the protein expression levels of cyclin D1, cyclin E2 and BCL2 apoptosis regulator, while it increased BCL2 associated X and tumor protein p53, all of which are involved in the regulation of cell cycle and apoptosis. Notably, the results obtained from in silico computational screening identified AKT serine/threonine kinase 1 (AKT1) and AKT2 as novel targets of resveratrol. Computational docking suggested that there are three or four possible hydrogen bonds in the active pocket of AKT1 and AKT2 that contribute to the mode of action of resveratrol. The present study confirmed that resveratrol bound to AKT1 and AKT2 with a pull-down assay. Furthermore, knockdown of AKT1 and AKT2 inhibited cell proliferation and colony growth, by attenuating cell cycle progression and increasing apoptosis in colon cancer cells, effects that were similar to those caused by resveratrol treatment. Taken together, the present results suggest that the targeting effects of resveratrol to AKT1 and AKT2 may be a potent strategy for chemoprevention or therapy for colon cancer.

International Journal of Molecular Medicine published new progress about Antitumor agents. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, Application In Synthesis of 501-36-0 .

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Bahramrezaie, Mojdeh; Amidi, Fardin; Aleyasin, Ashraf; Saremi, AboTaleb; Aghahoseini, Marzieh; Brenjian, Samaneh; Khodarahmian, Mahshad; Pooladi, Arash published the artcile< Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial.>, SDS of cas: 501-36-0, the main research area is HIF1 gene; Hormones; Intracytoplasmic sperm injection; Polycystic ovary syndrome; Resveratrol; VEGF gene.

OBJECTIVES: Management options for PCOS, as the most prevalent endocrine disorder in women of reproductive age, using natural supplements have a high priority for physicians, especially based on the etiological pathways. Therefore, this study was conducted to describe the effect of resveratrol on the angiogenesis pathway, for management of PCOS through assessing VEGF, HIF1 gene expression, and laboratory parameters. METHODS: In this triple-blind RCT, PCOS was confirmed in ICSI candidates based on the Rotterdam criteria. Sixty-two patients that met the inclusion criteria were randomly assigned to two groups. All patients took resveratrol 800 mg/day or placebo for 40 days orally from the beginning of their previous menstruation cycle until the oocyte retrieval day. The serum levels of different hormones were measured, and the expression of HIF1 & VEGF genes was quantified by real-time PCR. RESULTS: As for the laboratory hormone assay in 61 PCOS patients, a significant mean difference was seen in the FSH, LH, TSH, and testosterone between the two groups (P < 0.05). The results showed a reduction in the expression of VEGF & HIF1 genes under the effect of resveratrol in the granulosa cells (P = 0.0001). The number of mature oocytes, cleavage rate, fertilization rate, and fertility rate were not significantly different between the two groups (P > 0.05), but the high-quality oocyte rate and high-quality embryo rate were higher in the resveratrol group (P < 0.05). CONCLUSIONS: Based on the results, resveratrol may improve some outcomes of PCOS patients, probably through changing the serum levels of some sex hormones and expression of VEGF & HIF1 genes in the angiogenesis pathway of granulosa cells. Journal of assisted reproduction and genetics published new progress about 501-36-0. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, SDS of cas: 501-36-0.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Jeyaraman, Maya M; Al-Yousif, Nameer S H; Singh Mann, Amrinder; Dolinsky, Vernon W; Rabbani, Rasheda; Zarychanski, Ryan; Abou-Setta, Ahmed M published the artcile< Resveratrol for adults with type 2 diabetes mellitus.>, Recommanded Product: (E)-5-(4-Hydroxystyryl)benzene-1,3-diol, the main research area is .

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic disorder that is characterised by insulin resistance and hyperglycaemia, which over time may give rise to vascular complications. Resveratrol is a plant-derived nutritional supplement shown to have anti-diabetic properties in many animal models. Less evidence is available on its safety and efficacy in the management of T2DM in humans. OBJECTIVES: To assess the efficacy and safety of resveratrol formulations for adults with type 2 diabetes mellitus. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, PubMed, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and International Pharmaceutical Abstracts, as well as the International Clinical Trials Registry Platform (ICTRP) Search Portal and ClinicalTrials.gov. The date of the last search was December 2018 for all databases. No language restrictions were applied. SELECTION CRITERIA: All randomised controlled trials (RCTs) comparing effects of oral resveratrol (any dose or formulation, duration, or frequency of administration) with placebo, no treatment, other anti-diabetic medications, or diet or exercise, in adults with a diagnosis of T2DM. DATA COLLECTION AND ANALYSIS: Two review authors independently identified and included RCTs, assessed risk of bias, and extracted study-level data. Study authors were contacted for any missing information or for clarification of reported data. We assessed studies for certainty of the evidence using the GRADE instrument. MAIN RESULTS: We identified three RCTs with a total of 50 participants. Oral resveratrol not combined with other plant polyphenols was administered at 10 mg, 150 mg, or 1000 mg daily for a period ranging from four weeks to five weeks. The comparator intervention was placebo. Overall, all three included studies had low risk of bias. None of the three included studies reported long-term, patient-relevant outcomes such as all-cause mortality, diabetes-related complications, diabetes-related mortality, health-related quality of life, or socioeconomic effects. All three included studies reported that no adverse events were observed, indicating that no deaths occurred (very low-quality evidence for adverse events, all-cause mortality, and diabetes-related mortality). Resveratrol versus placebo showed neutral effects for glycosylated haemoglobin A1c (HbA1c) levels (mean difference (MD) 0.1%, 95% confidence interval (CI) -0.02 to 0.2; P = 0.09; 2 studies; 31 participants; very low-certainty evidence). Due to the short follow-up period, HbA1c results have to be interpreted cautiously. Similarly, resveratrol versus placebo showed neutral effects for fasting blood glucose levels (MD 2 mg/dL, 95% CI -2 to 7; P = 0.29; 2 studies; 31 participants), and resveratrol versus placebo showed neutral effects for insulin resistance (MD -0.35, 95% CI -0.99 to 0.28; P = 0.27; 2 studies; 36 participants). We found eight ongoing RCTs with approximately 800 participants and two studies awaiting assessment, which, when published, could contribute to the findings of this review. AUTHORS’ CONCLUSIONS: Currently, research is insufficient for review authors to evaluate the safety and efficacy of resveratrol supplementation for treatment of adults with T2DM. The limited available research does not provide sufficient evidence to support any effect, beneficial or adverse, of four to five weeks of 10 mg to 1000 mg of resveratrol in adults with T2DM. Adequately powered RCTs reporting patient-relevant outcomes with long-term follow-up periods are needed to further evaluate the efficacy and safety of resveratrol supplementation in the treatment of T2DM.

The Cochrane database of systematic reviews published new progress about 501-36-0 . 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, Recommanded Product: (E)-5-(4-Hydroxystyryl)benzene-1,3-diol.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Sattarinezhad, A.; Roozbeh, J.; Shirazi Yeganeh, B.; Omrani, G. R.; Shams, M. published the artcile< Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial>, SDS of cas: 501-36-0 , the main research area is resveratrol antioxidant albuminuria diabetic nephropathy; Albuminuria; Diabetes complications; Diabetes mellitus; Diabetic nephropathy; Resveratrol.

Albuminuria is the most important indicator of diabetic nephropathy (DN). Resveratrol, a natural compound found in grape skins and red wine, has antioxidant effects. This study aimed to evaluate the effects of resveratrol on DN.In this randomized, double-blind, placebo-controlled clin. trial, 60 patients with type 2 diabetes and albuminuria were randomly assigned to receive either resveratrol (500 mg/day) or placebo for 90 days. Losartan (12.5 mg/day) was also administered to all participants. Primary outcomes were urinary albumin/creatinine ratio, estimated glomerular filtration rate (eGFR) and serum creatinine levels. Secondary outcomes were oxidative stress markers, and anthropometric and biochem. measures. Mean urine albumin/creatinine ratio was significantly reduced in the resveratrol group vs placebo (-46.4 mg/g, 95% CI: -64.5 to -28.3 vs 29.9 mg/g, 95% CI: 4.9 to 54.9; P < 0.001), whereas eGFR (1.7 mL/min/1.73 m2, 95% CI: -3.4 to 6.8 vs -4.0, 95% CI: -8.2 to 0.2; P = 0.08) and serum creatinine (-0.3 mg/dL, 95% CI: -0.1 to 0.1 vs 0.1 mg/dL, 95% CI: -0.0 to 0.1; P = 0.13) were unchanged. Serum antioxidant enzymes were significantly increased with resveratrol. After adjusting for confounding variables, the effect of resveratrol in reducing urinary albumin excretion was still significant (P < 0.001). Regression anal. revealed that every 1-cm decrease in waist circumference and 1-μmol/L increase in nitric oxide (NO) was associated with 9.4 mg/g and 4.0 mg/g reductions, resp., of urine albumin/creatinine ratio. This clin. trial has shown that resveratrol may be an effective adjunct to angiotensin receptor blockers (ARBs) for reducing urinary albumin excretion in patients with DN (ClinicalTrials.gov: NCT02704494). Diabetes & Metabolism published new progress about Albuminuria. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, SDS of cas: 501-36-0 .

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Hou, Chih-Yao; Tain, You-Lin; Yu, Hong-Ren; Huang, Li-Tung published the artcile< The effects of resveratrol in the treatment of metabolic syndrome>, Reference of 501-36-0 , the main research area is resveratrol metabolic syndrome review; high-fat diet; metabolic syndrome; resveratrol; resveratrol derivatives.

A review. Resveratrol, also known as 3,5,4′-trihydroxystilbene, is a natural polyphenol that occurs as a phytoalexin. It is produced by plant sources such as grapes, apples, blueberries, plums, peanuts, and other oilseeds. This compound has a variety of effects on human health and diseases. This review summarizes the mounting evidence that resveratrol is helpful in treating metabolic syndrome and related disorders. Resveratrol can be provided either early as a reprogramming agent or later as part of treatment. A few of the main mechanisms underlying the beneficial effects of resveratrol on metabolic syndrome are outlined. This review also discusses the potential of resveratrol derivatives as a complementary or alternative medicine. In conclusion, resveratrol could be a useful regimen for the prevention and treatment of metabolic syndrome and its related conditions.

International Journal of Molecular Sciences published new progress about Cardiovascular disease. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, Reference of 501-36-0 .

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Jeandet, Philippe; Clement, Christophe; Cordelier, Sylvain published the artcile< Regulation of resveratrol biosynthesis in grapevine: new approaches for disease resistance?>, Related Products of 501-36-0 , the main research area is review phytoalexin resveratrol disease resistance.

A review. Transcription factors are key components in the regulation of metabolic pathways underlying numerous plant functions. Jiang et al. (2019) showed that the WRKY8 transcription factor fine-tunes biosynthesis of the phytoalexin resveratrol in grapevine through neg. regulation of the stilbene synthase gene. This paves the way for new approaches in our understanding of the regulation of phytoalexin biosynthesis in plants and, through this, improved phytoalexin production in engineered disease resistance.

Journal of Experimental Botany published new progress about Disease resistance, plant. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, Related Products of 501-36-0 .

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Simental-Mendia, Luis E.; Guerrero-Romero, Fernando published the artcile< Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial>, HPLC of Formula: 501-36-0 , the main research area is dyslipidemia lipid lowering agent resveratrol; Dyslipidemia; Lipid profile; Lipids; Randomized controlled trial; Resveratrol.

Objectives: The aim of this study was to explore the effect of resveratrol supplementation on lipid profile in individuals with dyslipidemia. Methods: Apparently healthy men and non-pregnant women 20 to 65 y of age with new diagnosis of dyslipidemia were enrolled in a randomized double-blind, placebo-controlled trial and randomly allocated to receive either resveratrol 100mg/d or placebo (sucrose 0.5 g/d) for 2 mo. Smoking, alc. intake, diabetes, acute or chronic renal or hepatic diseases, malignancy, cardiovascular disease, serum triacylglycerol levels ≥400mg/dL, low-d. lipoprotein cholesterol levels ≥190mg/dL, and consumption of lipid-lowering drugs or supplements containing resveratrol were exclusion criteria. Results: Seventy-one individuals with new diagnosis of dyslipidemia were enrolled and randomly allocated to the resveratrol (n = 35) or placebo groups (n = 36). At baseline, there were no significant differences between the study groups. After intervention period, individuals in the resveratrol group showed a significant decrease in total cholesterol (201.4 ± 34.4 vs. 220.6 ± 37.4, P = 0.04) and triacylglycerol (133.4 ± 55.3 vs. 166.7 ± 68.5, P = 0.04) concentrations compared with the placebo group, without significant statistical differences for high-d. lipoprotein cholesterol and low-d. lipoprotein cholesterol levels. Conclusion: The results suggest that resveratrol supplementation significantly reduces total cholesterol and triacylglycerol concentrations in individuals with dyslipidemia.

Nutrition (New York, NY, United States) published new progress about Dyslipidemia. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, HPLC of Formula: 501-36-0 .

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Ren, Boxu; Kwah, Marabeth Xin-Yi; Liu, Cuiliu; Ma, Zhaowu; Shanmugam, Muthu K.; Ding, Lingwen; Xiang, Xiaoqiang; Ho, Paul Chi-Lui; Wang, Lingzhi; Ong, Pei Shi; Goh, Boon Cher published the artcile< Resveratrol for cancer therapy: Challenges and future perspectives>, Recommanded Product: (E)-5-(4-Hydroxystyryl)benzene-1,3-diol, the main research area is review cancer resveratrol therapy; Cancer treatment; Pharmacodynamics; Pharmacokinetics; Resveratrol; Toxicity.

A review. Resveratrol (3,4′,5-trihydroxy-trans-stilbene) has been expected to ameliorate cancer and foster breakthroughs in cancer therapy. Despite thousands of preclin. studies on the anticancer activity of resveratrol, little progress has been made in translational research and clin. trials. Most studies have focused on its anticancer effects, cellular mechanisms, and signal transduction pathways in vitro and in vivo. In this review, we aimed to discern the causes that prevent resveratrol from being used in cancer treatment. Among the various limitations, poor pharmacokinetics and low potency seem to be the two main bottlenecks of resveratrol. In addition, resveratrol-induced nephrotoxicity in multiple myeloma patients hinders its further development as an anticancer drug. New insights and strategies have been proposed to accelerate the conversion of resveratrol from bench to bedside. In the interim, the most promising approach is to enhance the bioavailability of resveratrol with new formulations. Alternatively, more potent analogs of resveratrol could be developed to augment its anticancer potency. Given all the gaps mentioned, much work remains to be done. However, if remarkable progress can be made, resveratrol may finally be used for cancer therapy.

Cancer Letters (New York, NY, United States) published new progress about Antitumor agents. 501-36-0 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H12O3, Recommanded Product: (E)-5-(4-Hydroxystyryl)benzene-1,3-diol.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts